Veracyte, Inc.

New data published in ESMO Open show that Veracyte’s Prosigna Breast Cancer Assay significantly influenced treatment decisions for nearly one-third of physicians treating patients with early-stage breast cancer. Learn more about the study and how Prosigna can help guide more confident treatment decisions in this article authored by Jenna Lefkowits, our Executive Director for IVD Marketing & Strategy.

New findings derived from Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) tool suggest the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings, which could potentially help clinicians further individualize care based on each patient’s tumor biology, were presented today at ENDO 2024. #ENDO2024 #Endocrinology #ThyroidCancer https://lnkd.in/ewGuqB6C

Join us at ASCO 2024 to explore Veracyte’s innovative approach to minimal residual disease (MRD) detection. Our team is at booth 35131 and ready to discuss how our advanced whole-genome sequencing and AI capabilities are transforming cancer care in collaboration with our biopharma partners. #ASCO24 #AIinHealthcare #MRD

This morning at ASCO 2024: From 9 a.m. – 12 p.m. CDT, don’t miss several poster sessions that demonstrate the capabilities of Veracyte’s Prosigna Breast Cancer Assay and Decipher Bladder Genomic Classifier. Our team looks forward to discussing these presentations with the oncology community - stop by booth 35131 to connect with our experts! #ASCO24 #BreastCancer #BladderCancer

Day 1 at ENDO 2024! Stop by booth 709 to learn more about how our Afirma® Genomic Sequencing Classifier can help you personalize diagnosis and treatment for your patients with thyroid nodules, or book a meeting with Dr. Joshua Klopper, Veracyte’s Medical Director for Endocrinology. We’ll be here through Tuesday and look forward to connecting with you in Boston. https://lnkd.in/eKWxzuE6 #ThyroidCancer #Endocrinology #ENDO2024

Hello from the 2024 ASCO Annual Meeting! The Veracyte team is thrilled to be in Chicago and looks forward to connecting with others at the meeting – join us at booth 35131 to learn more about how we're transforming cancer care worldwide. #ASCO24 

A new clinical validation study published in European Urology highlights the potential of a whole-genome sequencing approach to revolutionize minimal residual disease (#MRD) detection in patients with muscle invasive bladder cancer. Developed by C2i Genomics, which was recently acquired by Veracyte, this innovative MRD method can help pave the way for more personalized and effective care for patients. Learn more about how this technology can transform MRD assessment and improve patient outcomes. https://lnkd.in/g994q5C9

On #WorldThyroidDay, we celebrate the strides made in personalizing diagnosis and treatment for thyroid nodules. For years, indeterminate thyroid nodules posed a significant challenge, often leading to unnecessary surgeries. At Veracyte, we are committed to driving innovation in this space, empowering clinicians with comprehensive insights to make more accurate treatment decisions, and helping patients navigate thyroid nodule diagnosis. #ThyroidCancer #endocrinology 

New data from three studies, to be presented at #ENDO2024 next month, will demonstrate the power of Veracyte's Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help to further personalize treatment of the disease. Learn more: #ThyroidCancer #endocrinology

Reflecting on the 2024 AUA Annual Meeting, we were inspired by the innovations in prostate cancer care through molecular diagnostics. Dr. Phillip G. Febbo, MD, our Chief Scientific Officer and Chief Medical Officer, shares his insights on this evolution, emphasizing the importance of making these advancements accessible to all communities. He also discusses the crucial role of molecular assays like Veracyte’s Decipher Prostate Genomic Classifier in personalized care.   #ProstateCancer #AUA2024 #HealthEquity